This fall, The American Journal of Managed Care® convened a panel of experts on migraine to discuss calcitonin gene-related peptide (CGRP) inhibitors, an emerging therapy for the condition, which affects 39 million people in the United States.
In May, the FDA approved erenumab, the first calcitonin gene-related peptide (CGRP) inhibitor for the prevention of migraine in adults. Since then, 2 other CGRP inhibitors have gained approval, providing a new class of drugs for those who suffer from migraine.
This fall, The American Journal of Managed Care® convened a panel of experts on migraine to discuss the emerging therapy for the condition, which affects 39 million people in the United States.
Log in to listen to the podcast.
Listen above or through one of these podcast services:
FDA Approves Erenumab, First CGRP Inhibitor for Prevention of Migraine
Erenumab for Migraine Is Cost-Effective, but Long-Term Harms Remain Unclear
ICER Releases Final Evidence Report on Efficacy, Cost Effectiveness of CGRP Inhibitors for Migraine
Migraine Survey Highlights Significant Lack of Awareness of CGRP Inhibitors
CGRP Inhibitor Erenumab Shows Efficacy in Migraine Within 1 Week